Internal Merck documents showed the company knew Vioxx increased heart attack risk by 2000 but continued marketing until 2004. FDA emails revealed regulatory capture concerns.
“Merck is committed to the safety of patients who use our medicines”
From “crazy” to confirmed
The Claim Is Made
This is the moment they called it crazy.
In 1999, Merck released Vioxx, a pain reliever that promised arthritis sufferers relief without the stomach problems associated with traditional NSAIDs. Within five years, the drug had become a blockbuster, generating over $2.5 billion annually. What patients didn't know was that Merck's own scientists had already discovered something troubling in their internal research: the drug appeared to nearly double the risk of heart attacks and strokes.
The official story from Merck and regulators was straightforward. Vioxx was safe. When cardiovascular concerns were raised, company representatives suggested that any risks were unproven or required more study. The FDA, which had approved the drug and continued to oversee it, accepted these reassurances. Doctors prescribed it by the millions. Patients took it believing the regulatory system had done its job.
But the internal documents told a different story. Merck researchers had documented cardiovascular risks in their studies going back to 1996—years before Vioxx even hit the market. One pivotal study, the VIGOR trial from 2000, showed a fourfold increase in heart attacks among Vioxx users compared to a competitor drug. Rather than treat this as a red flag, Merck's marketing teams downplayed the finding in presentations to doctors and continued selling the drug aggressively.
The company even faced a problem: their own safety data was becoming harder to ignore. Yet for four years after the VIGOR trial, Merck continued promoting Vioxx to millions of patients. The drug remained on shelves while the company knew—through their own rigorous research—that it posed a serious cardiac risk to a substantial portion of users.
What finally forced action wasn't safety data. It was external pressure. In September 2004, results from another study became public and could no longer be contained within corporate walls. Only then did Merck withdraw Vioxx from the market. By that point, an estimated 140,000 Americans had suffered heart attacks or strokes associated with the drug. Thousands died.
Get the 5 biggest receipts every week, straight to your inbox — plus an exclusive PDF: The Top 10 Conspiracy Theories Proven True in 2025-2026. No spam. No agenda. Just the papers they couldn't hide.
You just read "Merck Concealed Heart Attack Risks of Vioxx Despite Internal…". We send ones like this every week.
No one's said anything yet. Be the first to drop your take.
The FDA's role in this failure remains contested. Emails and documents released during subsequent litigation suggested regulators were aware of cardiovascular signals but accepted Merck's explanations without demanding the company take more aggressive action. Whether this constituted regulatory capture—where industry influence compromises oversight—remains debated, but the timeline was clear: regulators moved slowly while patients continued being harmed.
Merck eventually paid $4.85 billion to settle lawsuits related to Vioxx, making it one of the largest pharmaceutical settlements in history. Yet the company admitted no wrongdoing, and no individual executive faced criminal charges. The structural problems that allowed this situation—industry-friendly regulators, the ability to minimize unfavorable internal data, incentives that prioritize sales over safety—remained unchanged.
The Vioxx case matters not because it represents an isolated failure. It matters because it demonstrates what happens when the institutions meant to protect public health become permissive of corporate practices that endanger patients. It shows that "we didn't know" is not always an acceptable defense when the knowledge existed inside company walls. And it suggests that in the pharmaceutical industry, profit can sometimes overwhelm safety—until the damage becomes too visible to ignore.
Beat the odds
This had a 1.7% chance of leaking — someone talked anyway.
Conspirators
~200Network
Secret kept
21.6 years
Time to 95% exposure
500+ years
